Sesquiterpenoids as well as extraction method and application thereof
By extracting sesquiterpenes from the rhizomes of curcuma in Guangxi Zhuang Autonomous Region and preparing anti-inflammatory drugs, the problem of failure to fully utilize the medicinal value of curcuma in the existing technology has been solved, and the inhibition and anti-inflammatory activities on liver cancer cells have been achieved. Provides new directions for drug development.
Patent Information
- Application Number
- CN202410801705.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-20
AI Technical Summary
The prior art has failed to fully utilize the sesquiterpenes in the rhizomes of curcuma in Guangxi Zhuang Autonomous Region, especially in the application of anti-inflammatory drugs, and its medicinal value has not been fully utilized.
By extracting sesquiterpenes from the rhizomes of Curcuma zedora in Guangxi Zhuang Autonomous Region, new sesquiterpenes are obtained and used for the use of the steps of reflux extraction of ethanol aqueous solution, reflux extraction, ethyl acetate extraction, silica gel column chromatography separation and HPLC purification. Prepare anti-inflammatory drugs.
The new sesquiterpene compounds were successfully extracted, showing an inhibitory effect on liver cancer cells and inhibiting NO production in LPS-induced RAW264.7 cells, providing a new active lead compound for anti-inflammatory drugs, which is the Zhuang people in Guangxi. The theoretical foundation has been laid in the deep research and development of Curcuma zedo in the autonomous region.
Smart Images

Figure CN118908920A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of traditional Chinese medicine extraction, and particularly relates to a sesquiterpenoid compound separated from the rhizome of Curcuma zedoariae in Guangxi Zhuang Autonomous Region, an extraction method thereof, and application of the sesquiterpenoid compound in preparing anti-inflammatory drugs. Background Art
[0002] Curcuma kwangsiensis SGLee et CFLing is a perennial herb of the genus Curcuma in the Zingiberaceae family. It is mainly distributed in Guangxi Zhuang Autonomous Region and Yunnan Province of my country. It is also known as Gui Curcuma and Mao Curcuma. According to the Pharmacopoeia of the People's Republic of China (2020 Edition, Part I), Curcuma kwangsiensis is one of the three major source plants of the traditional Chinese medicine Curcuma. Its main effects are promoting qi and removing blood, eliminating accumulation and relieving pain (National Pharmacopoeia Committee, Pharmacopoeia of the People's Republic of China [M]. Beijing: China Medical Science and Technology Press. 2020). Sesquiterpenes, diarylheptanes and diterpenoids are the main chemical components of Curcuma kwangsiensis. Modern pharmacology shows that curcumin isolated from Curcuma zedoaria in Guangxi Zhuang Autonomous Region has significant anti-tumor activity, especially against liver cancer, skin cancer, pancreatic cancer, prostate cancer and ovarian cancer (Perrone D, Ardito F, Giannatempo G, et al. Biological and therapeutic activities, and anticancer properties of curcumin [J]. Experimental and Therapeutic Medicine, 2015, 10 (5): 1615-1623.). Zeng Jianhong et al. studied the effect of Curcuma kwangsiensis polysaccharides on human nasopharyngeal carcinoma cell line CNE-2 cells and found that the polysaccharides from Curcuma kwangsiensis had a significant inhibitory effect on the proliferation of CNE-2 cells. They believed that its mechanism of action may be to weaken the expression of Bcl-2-mediated apoptosis induction and promote the expression of p53 (Zeng JH, Dai P, Ren LY, et al. Apoptosis-induced anti-tumor effect of Curcuma kwangsiensis polysaccharides against human nasopharyngeal carcinoma cells [J]. Carbohydrate Polymers, 2012, 89 (4): 1067-1072.). In addition, the salvialane-type sesquiterpenes isolated from Curcuma kwangsiensis by Liao Haibing et al. have good anti-inflammatory activity, and their IC 50The value of sesquiterpenoid compounds from Curcuma kwangsiensis was 1.85±0.44μM (Liao HB, Feng WY, Wang HS, et al. Sesquiterpenoid compounds from Curcuma kwangsiensis[J]. Chemistry&Biodiversity, 2019, 16(5): e1900123.). In order to maximize the medicinal value of Curcuma zedoaria from Guangxi Zhuang Autonomous Region, the rhizomes of Curcuma zedoaria from Guangxi Zhuang Autonomous Region were systematically studied, new sesquiterpenoid compounds were extracted, the structures of the compounds were confirmed by nuclear magnetic resonance, infrared, mass spectrometry and other methods, and their anti-inflammatory activity was detected. Summary of the invention
[0003] The primary purpose of the present invention is to provide a sesquiterpene compound.
[0004] The second object of the present invention is to provide a method for extracting sesquiterpenoid compounds.
[0005] The third object of the present invention is to provide a pharmaceutical composition containing sesquiterpenoid compounds.
[0006] The fourth object of the present invention is to provide a sesquiterpenoid compound or an isomer of the compound, a pharmaceutically acceptable salt of the compound or a pharmaceutical composition comprising the compound for use in the preparation of anti-inflammatory drugs.
[0007] The technical solution of the present invention is summarized as follows:
[0008] A sesquiterpenoid compound, which is any one of the compounds shown in the following structural formulas 1-3 or an isomer of the compound, or a pharmaceutically acceptable salt of the compound.
[0009]
[0010] The pharmaceutically acceptable salts include sodium salt, potassium salt, ammonium salt, hydrochloride and sulfate.
[0011] The isomers include optical isomers, cis-trans isomers, racemates and mixtures thereof.
[0012] The present invention also provides a method for extracting the sesquiterpenoid compounds 1-3, comprising the following steps:
[0013] (1) Using the dried rhizome of Curcuma zedoaria from Guangxi Zhuang Autonomous Region as raw material, adding 95% ethanol aqueous solution with a volume concentration of 8 to 15 times the mass of the raw material, reflux extraction 2 to 4 times, each extraction time 2 to 4 hours, combining to obtain extracts, recovering the solvent under reduced pressure, and concentrating to obtain a total extract;
[0014] (2) dispersing the total extract into 5 to 10 times the mass of water, and extracting with ethyl acetate to obtain an ethyl acetate layer and an aqueous layer;
[0015] (3) The ethyl acetate extract concentrate was separated by silica gel column chromatography using a gradient elution with petroleum ether-ethyl acetate in a volume ratio of 100:0 to 0:1 as the eluent, and fractions E1 with a volume ratio of 100:0, E2 with a volume ratio of 50:1, E3 with a volume ratio of 20:1, E4 with a volume ratio of 2:1, and E5 with a volume ratio of 0:1 were collected;
[0016] (4) The concentrated fraction E3 was separated by silica gel column chromatography and gradient elution was performed using petroleum ether-ethyl acetate in a volume ratio of 100:1 to 0:1 to obtain compound 1-3.
[0017] The step (4) specifically comprises:
[0018] Fraction E3 was concentrated and separated by silica gel column chromatography, and the fraction with a volume ratio of petroleum ether to ethyl acetate of 15:1 was collected and recorded as E32;
[0019] Fraction E32 was concentrated and separated by MCI column chromatography, and fractions eluted with 70% and 80% methanol-water volume concentrations were collected and recorded as E321;
[0020] Fraction E321 was concentrated and separated by ODS column chromatography, and gradient eluted with methanol-water in volume ratios of 9:1, 7:3, 5:5, 3:7, 2:8, and 1:0, and the fraction with a volume ratio of 5:5 was collected and recorded as E3214;
[0021] Fraction E3214 was concentrated and separated by silica gel column chromatography, and fractions containing petroleum ether and acetone in a volume ratio of 20:1 and 8:1 were collected and recorded as E32142 and E32144;
[0022] Fraction E32142 was concentrated and separated by Sephadex LH-20 column chromatography (CH3OH) to obtain fraction E321422;
[0023] Fraction E321422 was purified by preparative HPLC chromatography using methanol-water in a volume ratio of 60:40 as the mobile phase to obtain compound 1;
[0024] Fraction E32144 was purified by preparative HPLC chromatography using methanol-water in a volume ratio of 50:50 as the mobile phase to obtain compounds 2 and 3.
[0025] Extract of Curcuma zedoaria rhizome from Guangxi Zhuang Autonomous Region containing sesquiterpenoids.
[0026] Application of Curcuma zedoaria rhizome extract in the preparation of anti-inflammatory drugs in Guangxi Zhuang Autonomous Region.
[0027] A pharmaceutical composition, comprising one or more of the sesquiterpenoid compound, the isomer of the compound, and the pharmaceutically acceptable salt of the compound; and further comprising one or a combination of pharmaceutically acceptable carriers, excipients, and diluents. The pharmaceutical composition is administered orally or by injection, and the dosage forms include tablets, capsules, powders, syrups, and injections.
[0028] The present invention also provides the use of the sesquiterpenoid compound, the isomer of the compound, the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in the preparation of anti-inflammatory drugs.
[0029] Advantages of the present invention:
[0030] The sesquiterpenoid compound or its isomer, a pharmaceutically acceptable salt or a pharmaceutical composition containing the compound of the present invention has an inhibitory effect on liver cancer cells and can be used to prepare anti-inflammatory drugs. The present invention further enriches the structural diversity of active substances in the rhizomes of Curcuma zedoaria in Guangxi Zhuang Autonomous Region, and on this basis, lays a foundation for the subsequent relevant biological activity tests of the obtained monomer compounds, provides active lead compounds for the development of new drugs, and also provides a theoretical basis for the in-depth research and development of Curcuma zedoaria in Guangxi Zhuang Autonomous Region.
[0031] The sesquiterpenoid compound of the invention has an inhibitory effect on NO production in LPS-induced RAW264.7 cells and can be used for preparing anti-inflammatory drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Inhibitory activity of compounds 1-2 on LPS-induced NO production in RAW264.7 cells. DETAILED DESCRIPTION
[0033] The technical solution of the present invention will be further described below in conjunction with specific embodiments.
[0034] Example 1
[0035] The method for extracting sesquiterpenoid compounds from Curcuma zedoaria in Guangxi Zhuang Autonomous Region comprises the following steps:
[0036] (1) Using 20.0 kg of dried rhizomes of Curcuma zedoaria from Guangxi Zhuang Autonomous Region as raw material, adding 95% ethanol aqueous solution with a volume concentration of 10 times the mass of the raw material, reflux extraction 3 times, each extraction for 3 hours, combining to obtain extracts, recovering the solvent under reduced pressure, and concentrating to obtain a total extract;
[0037] (2) The total extract was dispersed in 8 times the mass of water and extracted with ethyl acetate to obtain an ethyl acetate layer (570.0 g) and an aqueous layer;
[0038] (3) The concentrated ethyl acetate extract was separated by silica gel column chromatography using petroleum ether-ethyl acetate in a volume ratio of 100:0 to 0:1 as an eluent for gradient elution, collecting fractions E1 (55.0 g) with a volume ratio of 100:0, fractions E2 (175.0 g) with a volume ratio of 50:1, fractions E3 (129.1 g) with a volume ratio of 20:1, fractions E4 (99.6 g) with a volume ratio of 2:1; and fractions E5 (73.3 g) with a volume ratio of 0:1;
[0039] (4) The concentrated fraction E3 was separated by silica gel column chromatography and gradient elution was performed using petroleum ether-ethyl acetate in a volume ratio of 100:1 to 0:1 to obtain compound 1-3.
[0040] Fraction E3 (129.1 g) was concentrated and separated by silica gel column chromatography, and the fraction with a volume ratio of petroleum ether to ethyl acetate of 15:1 was collected and recorded as E32 (30.8 g);
[0041] Fraction E32 was concentrated and separated by MCI column chromatography, and the fractions eluted with 70% and 80% methanol water were collected and recorded as E321 (26.2 g);
[0042] Fraction E321 was concentrated and separated by ODS column chromatography, and gradient eluted with methanol-water in volume ratios of 9:1, 7:3, 5:5, 3:7, 2:8, and 1:0, and the fraction with a volume ratio of 5:5 was collected and recorded as E3214 (5.3 g);
[0043] Fraction E3214 was concentrated and separated by silica gel column chromatography, and fractions with a volume ratio of petroleum ether to acetone of 20:1 and 8:1 were collected and recorded as E32142 (660.9 mg) and E32144 (1.0 g);
[0044] Fraction E32142 was concentrated and separated by Sephadex LH-20 column chromatography (CH3OH) to obtain fraction E321422 (520.1 mg);
[0045] Fraction E321422 was purified by preparative HPLC chromatography using methanol-water in a volume ratio of 60:40 as the mobile phase to obtain compound 1 (2.9 mg);
[0046] Fraction E32144 was purified by preparative HPLC chromatography using methanol-water in a volume ratio of 50:50 as the mobile phase to obtain compounds 2 (2.8 g) and 3 (1.1 mg).
[0047] The structures of the extracted and separated sesquiterpenoid compounds 1-3 were identified, and the specific physicochemical data are as follows:
[0048] Compound 1: Colorless oil, turns pink-purple after heating with 1% vanillin-concentrated sulfuric acid. +27.0 (c=0.10, CH3OH), HR-ESI-MS gives quasi-molecular ion peak [M+Na] + m / z:273.1480(calcd.for C 15 H 22 O3Na + ,273.1467), whose molecular formula is C 15 H 22 O3, 1 H-NMR (600 MHz, CD3OD) and 13 C-NMR (150 MHz, CD3OD) data are shown in Table 1.
[0049] Compound 2: Colorless oil, turns pink-purple after heating with 1% vanillin-concentrated sulfuric acid. –16.1 (c=0.10, CH3OH), HR-ESI-MS gives quasi-molecular ion peak [M+Na] + m / z:289.1411(calcd.for C 15 H 22 O4Na + ,289.1416), whose molecular formula is C 15 H 22 O4, 1 H-NMR (600 MHz, CD3OD) and 13 C-NMR (150 MHz, CD3OD) data are shown in Table 2.
[0050] Compound 3: a colorless oil, which turns pink-purple after heating with 1% vanillin-concentrated sulfuric acid. -26.8 (c = 0.10, CH3OH), HR-ESI-MS gives a quasi-molecular ion peak [M+Na] + m / z:275.1618 (calcd.for C 15 H 24 O3Na + ,275.1623), whose molecular formula is C 15 H 24 O3, 1 H-NMR (600 MHz, CD3OD) and 13 C-NMR (150 MHz, CD3OD) data are shown in Table 3.
[0051] Table 1 1 H-NMR (600MHz), 13 C-NMR(150MHz)data of compound 1(CD3OD)
[0052]
[0053] Table 2 1 H-NMR (600MHz), 13 C-NMR(150MHz)data of compound 2(CD3OD)
[0054]
[0055] Table 3 1 H-NMR (600MHz), 13 C-NMR(150MHz)data of compound 3(CD3OD)
[0056]
[0057] Through physical and chemical data and modern spectroscopic methods (HRESIMS and NMR), combined with relevant data from public literature, the structures of the above compounds were identified, and it was determined that compounds 1-3 were all new compounds not reported in the literature, as shown below:
[0058]
[0059] Example 2
[0060] (1) Using the dried rhizome of Curcuma zedoaria from Guangxi Zhuang Autonomous Region as raw material, adding 95% ethanol aqueous solution with a volume concentration of 8 times the mass of the raw material, reflux extraction twice, each extraction for 2 hours, combining to obtain the extract, reducing the pressure to recover the solvent, and concentrating to obtain the total extract;
[0061] (2) dispersing the total extract into 5 times the mass of water, extracting with ethyl acetate to obtain an ethyl acetate layer and an aqueous layer;
[0062] (3) The ethyl acetate extract concentrate was separated by silica gel column chromatography using a gradient elution with petroleum ether-ethyl acetate in a volume ratio of 100:0 to 0:1 as the eluent, and fractions E1 with a volume ratio of 100:0, E2 with a volume ratio of 50:1, E3 with a volume ratio of 20:1, E4 with a volume ratio of 2:1, and E5 with a volume ratio of 0:1 were collected;
[0063] (4) The concentrated fraction E3 was separated by silica gel column chromatography and further purified by gradient elution with petroleum ether-ethyl acetate in a volume ratio of 100:1 to 0:1 to obtain compound 1-3. The specific separation and purification process was the same as in Example 1.
[0064] Example 3
[0065] (1) Using the dried rhizome of Curcuma zedoaria from Guangxi Zhuang Autonomous Region as raw material, adding 95% ethanol aqueous solution with a volume concentration of 15 times the mass of the raw material, reflux extraction 4 times, each extraction for 4 hours, combining to obtain the extract, reducing pressure to recover the solvent, and concentrating to obtain the total extract;
[0066] (2) dispersing the total extract into 10 times the mass of water, and extracting with ethyl acetate to obtain an ethyl acetate layer and an aqueous layer;
[0067] (3) The ethyl acetate extract concentrate was separated by silica gel column chromatography using a gradient elution with petroleum ether-ethyl acetate in a volume ratio of 100:0 to 0:1 as the eluent, and fractions E1 with a volume ratio of 100:0, E2 with a volume ratio of 50:1, E3 with a volume ratio of 20:1, E4 with a volume ratio of 2:1, and E5 with a volume ratio of 0:1 were collected;
[0068] (4) The concentrated fraction E3 was separated by silica gel column chromatography and further purified by gradient elution with petroleum ether-ethyl acetate in a volume ratio of 100:1 to 0:1 to obtain compound 1-3. The specific separation and purification process was the same as in Example 1.
[0069] The effects of the sesquiterpenoid compounds 1-2 obtained by the above extraction on the anti-inflammatory activity of mouse macrophages RAW264.7 were studied as follows:
[0070] 1. Principle: Excessive LPS will induce the activation of nitric oxide synthase (NOS) in macrophages and produce NO. NO reacts rapidly with oxygen free radicals to form NO2 - , the formed NO2 - Under acidic conditions, it can be quantitatively detected by Griess Reagent. - It undergoes a diazotization reaction with sulfanilamide, and then undergoes a coupling reaction with N-1-naphthylethylene-diaminedihydrochloride to generate a purple-red azo compound. Finally, its absorbance value is measured at 540nm using an enzyme marker. Combined with the standard curve, the NO content in the sample can be obtained.
[0071] 2. Methods: Take logarithmic-phase mouse mononuclear macrophage RAW264.7 cells and adjust the cell concentration to 3.5×104 cells / well were inoculated in a 96-well plate, and 100 μL of cell suspension was added to each well. In the experiment, a control group (RAW264.7 cells, DMSO), a model group (RAW264.7 cells, DMSO, 0.5 μg / mL of LPS), a positive drug group (RAW264.7 cells, dexamethasone (20 μM), 0.5 μg / mL of LPS) and a test drug group (RAW264.7 cells, test compounds (20 μM), 0.5 μg / mL of LPS) were set up at the same time. The cells were cultured and incubated in a 5% CO2, 37°C constant temperature incubator for 24 hours, and then 40 μL of cell supernatant was aspirated and placed in an ELISA plate. An equal volume of Griess reagent was added to measure the accumulation of nitrite in the culture medium at 540 nm using an ELISA reader. The results are shown in Figure 2. Figure 1 As shown, compound 1 has a slight inhibitory activity on NO release.
[0072] The above embodiments are only used to help understand the method and the central idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the protection of the claims of the present invention.
Claims
1. A sesquiterpenoid compound, It is characterized in that It is any one of the compounds represented by the following structural formulas 1-3 or any one of the pharmaceutically acceptable salts of the compound; 2. The method for extracting sesquiterpenoids according to claim 1, It is characterized in that The steps include: (1) using dried rhizomes of Curcuma zedoaria from Guangxi Zhuang Autonomous Region as raw materials, adding ethanol aqueous solution of 8 to 15 times the mass of the raw materials, reflux extraction, combining to obtain extracts, recovering the solvent under reduced pressure, and concentrating to obtain a total extract; (2) dispersing the total extract into 5 to 10 times the mass of water, and extracting with ethyl acetate to obtain an ethyl acetate layer and an aqueous layer; (3) The ethyl acetate extract concentrate was separated by silica gel column chromatography using petroleum ether-ethyl acetate in a volume ratio of 100:0 to 0:1 as an eluent for gradient elution, collecting fractions E1 with a volume ratio of 100:0, E2 with a volume ratio of 50:1, E3 with a volume ratio of 20:1, E4 with a volume ratio of 2:1, and E5 with a volume ratio of 0:1; (4) The concentrated fraction E3 was separated by silica gel column chromatography using a gradient elution with petroleum ether-ethyl acetate in a volume ratio of 100:1 to 0:1 to obtain compound 1-3.
3. The method for extracting sesquiterpenoids according to claim 2, It is characterized in that The specific separation and purification process of fraction E3 in step (4) is as follows: Fraction E3 was concentrated and separated by silica gel column chromatography, and the fraction with a volume ratio of petroleum ether to ethyl acetate of 15:1 was collected and recorded as E32; Fraction E32 was concentrated and separated by MCI column chromatography, and the fractions eluted with 70% and 80% methanol water were collected and recorded as E321; Fraction E321 was concentrated and separated by ODS column chromatography, and gradient eluted with methanol-water in volume ratios of 9:1, 7:3, 5:5, 3:7, 2:8, and 1:0, and the fraction with a volume ratio of 5:5 was collected and recorded as E3214; Fraction E3214 was concentrated and separated by silica gel column chromatography, and fractions containing petroleum ether and acetone in a volume ratio of 20:1 and 8:1 were collected and recorded as E32142 and E32144; Fraction E32142 was purified to obtain compound 1, and fraction E32144 was purified to obtain compounds 2 and 3.
4. The method for extracting sesquiterpenoids according to claim 3, It is characterized in that The fractions E32142 and E32144 are purified by: Fraction E32142 was concentrated and purified by CH 3 OH was used as the eluent, and the fraction E321422 was obtained by Sephadex LH-20 column chromatography; Fraction E321422 was purified by preparative HPLC chromatography using methanol-water in a volume ratio of 60:40 as the mobile phase to obtain compound 1; Fraction E32144 was purified by preparative HPLC chromatography using methanol-water in a volume ratio of 50:50 as the mobile phase to obtain compounds 2 and 3.
5. A pharmaceutical composition, It is characterized in that The invention comprises one or more of the sesquiterpenoid compound as claimed in claim 1 or a pharmaceutically acceptable salt of the compound; and further comprises one or a combination of a pharmaceutically acceptable carrier, an excipient, and a diluent.
6. The pharmaceutical composition according to claim 5, It is characterized in that The administration route of the pharmaceutical composition is oral administration or injection administration, and the dosage forms include: tablets, capsules, powders, syrups and injections.
7. An extract of the rhizome of Curcuma zedoaria from Guangxi Zhuang Autonomous Region, It is characterized in that The invention comprises the sesquiterpenoid compound according to claim 1.
8. Use of the sesquiterpenoid compound according to claim 1 in the preparation of anti-inflammatory drugs.
9. Use of the pharmaceutical composition according to claim 5 or 6 in the preparation of anti-inflammatory drugs.
Citation Information
Patent Citations
Chroman type or chromene type meroterpenoid compound as well as extraction method and application thereof
CN114853712A
Method for evaluating adverse reaction of sesquiterpenoids in zedoary turmeric oil
US20230251203A1
Cited By
Polyphenolic compound as well as preparation method and application thereof
CN119930417A
Xanthomectin compound as well as extraction method and application thereof
CN120117973A
Chromene type meroterpenoid compound as well as extraction method and application thereof
CN120118075A
Method for extracting neonorsesquiterpenes from stems and leaves of rhizoma arisaematis and application of neonorsesquiterpenes
CN120136829A
